# Everolimus, Cetuximab and Capecitabine in Patients With Metastatic Pancreatic Cancer

> **NCT01077986** · PHASE1,PHASE2 · COMPLETED · sponsor: **Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)** · enrollment: 35 (actual)

## Conditions studied

- Metastatic Pancreatic Cancer

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Cetuximab
- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT01077986
- **Lead sponsor:** Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2010-08
- **Final completion:** 2011-08
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2021-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01077986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01077986, "Everolimus, Cetuximab and Capecitabine in Patients With Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01077986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*